Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapansutrile - Olatec Therapeutics

Next Previous
X
Search
Drug Profile

Dapansutrile - Olatec Therapeutics

Alternative Names: OLT 1177; OLT1177

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Olatec Industries
  • Developer Olatec Therapeutics; University of Innsbruck
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiasthmatics; Antidementias; Antigouts; Antineoplastics; Antiparkinsonians; Antirheumatics; Antivirals; Cardiovascular therapies; Heart failure therapies; Nitriles; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Inflammasome inhibitors; Interleukin 1 beta inhibitors; Interleukin 18 inhibitors; Interleukin inhibitors; NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Gout
  • Phase II COVID 2019 infections; Musculoskeletal pain; Schnitzler syndrome; Type 2 diabetes mellitus
  • Phase I/II Malignant melanoma
  • Preclinical Alzheimer's disease; Arthritis; Asthma; Breast cancer; Contact dermatitis; Multiple sclerosis; Myocardial infarction; Pancreatic cancer; Parkinson's disease; Spinal cord injuries
  • No development reported Heart failure; Myocardial reperfusion injury

Most Recent Events

  • 03 Jul 2024 Phase-II clinical trials in Type 2 diabetes mellitus (In adults, In the elderly) in Switzerland (PO) (NCT06047262)
  • 20 Feb 2024 Olatec Therapeutics plans a phase II trial in Parkinson's disease (Early-stage disease) in United Kingdom (PO) in mid-2024
  • 02 Feb 2024 Olatec Therapeutics terminates a phase II trial in Schnitzler syndrome (Treatment-experienced, In adults, In the elderly) in Netherlands (PO), due to trial design issues that did not allow for determination of efficacy and safety (EudraCT-2017-003282-98) (NCT03595371)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top